PLX compared with VNCE: revenue, margins and what each company keeps, and the suppliers and customers both name

PLXProtalix BioTherapeutics, Inc.

Mkt capRevenueRevenue

VNCEVince Holding Corp.

Mkt capRevenueRevenue

Compare

PLXProtalix BioTherapeutics, Inc.

VNCEVince Holding Corp.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PLX

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±12.4%▲+7.82%×0.63

May 13 '26±17.0%▲+1.05%×0.06

Q1 FY26±15.2%▼−20.79%×1.37

Q3 FY25±28.3%▼−9.81%×0.35

VNCE1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−21.16%—

= impliedPLX realized, solidVNCE realized, hatchedOne scale, both sides: full bar = 29%× = |realized| ÷ impliedSource: market data

PLXProtalix BioTherapeutics, Inc.

2.60▼−0.57%· post 2.60

Mkt cap$208.7MRevenue$20MQ2 FY26Revenue$53MFY25

VNCEVince Holding Corp.

10.64▲+0.42%· post 10.66

ClosedOct 30 '26

Mkt cap$138.1MRevenue$82MQ2 FY26Revenue$300MFY25

Compare

ClosedOct 30 '26

PLXProtalix BioTherapeutics, Inc.

VNCEVince Holding Corp.

2.60▼−0.57%post 2.60

Price

10.64▲+0.42%post 10.66

$208.7M

Mkt cap

$138.1M

Q2 FY26$20M

Revenue

$82MQ2 FY26

FY25$53M

Revenue

$300MFY25

PLX2.60▼−0.57%vsVNCE10.64▲+0.42%ClosedOct 30 '26